Other tumor ISGs regulated by type I IFNs such as NOS2 (Jacquelot et al, 2019) and CD38 (Chen et al, 2018a) can also have immune-suppressive effects and have been implicated to promote resistance to PD-1 pathway blockade. Here, CD38 is linked to neoplasm.